Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective, Long-Term, Interventional, Active Extension Study to Evaluate the Safety and Tolerability of NBI-921352 as Adjunctive Therapy in Subjects With Focal Onset Seizures (FOS)

NCT05493293 is registered in ClinicalTrials.gov with Neurocrine Biosciences as lead sponsor.

NCT NCT05493293
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05493293 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective, Long-Term, Interventional, Active Extension Study to Evaluate the Safety and Tolerability of NBI-921352 as Adjunctive Therapy in Subjects With Focal Onset Seizures (FOS)
Lead sponsor
Neurocrine Biosciences
Phase
Phase 2
Overall status
Terminated
Start date
November 9, 2022
Completion date
March 11, 2024
Enrollment
82 (actual)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

focal onset epilepsy, focal onset seizure